ENTRY       D07603                      Drug
NAME        Caffeine citrate (USP);
            Cafcit (TN)
PRODUCT     CAFFEINE CITRATE (Hikma Pharmaceuticals USA)
  GENERIC   CAFFEINE CITRATE (American Regent)
            CAFFEINE CITRATE (Armas Pharmaceuticals)
            CAFFEINE CITRATE (AuroMedics Pharma LLC)
            CAFFEINE CITRATE (Exela Pharma Sciences)
            CAFFEINE CITRATE (Exela Pharma Sciences)
            CAFFEINE CITRATE (Exela Pharma Sciences)
            CAFFEINE CITRATE (Exela Pharma Sciences)
            CAFFEINE CITRATE (Fresenius Kabi USA)
            CAFFEINE CITRATE (Fresenius Kabi USA)
            CAFFEINE CITRATE (Fresenius Kabi USA)
            CAFFEINE CITRATE (Micro Labs Limited)
            CAFFEINE CITRATE (Micro Labs Limited)
            CAFFEINE CITRATE (Sagent Pharmaceuticals)
            CAFFEINE CITRATE (Sun Pharmaceutical Industries)
            CAFFEINE CITRATE (Sun Pharmaceutical Industries)
            CAFFEINE CITRATE ORAL SOLUTION (Armas Pharmaceuticals)
FORMULA     C8H10N4O2. C6H8O7
EXACT_MASS  386.1074
MOL_WEIGHT  386.3141
CLASS       Respiratory system agent
             DG01616  Xanthine derivative
              DG01612  Xanthine-type central nervous system stimulant
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG02855  CYP2E1 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: D11AX26 N06BC01
            Chemical structure group: DG00974
            Product (DG00974): D00528<JP> D01453<JP> D07603<US>
EFFICACY    Stimulant (central), Analeptic, Adenosine receptor antagonist, Phosphodiesterase inhibitor
COMMENT     Xanthine derivative
TARGET      ADORA1 [HSA:134] [KO:K04265]
            ADORA2A [HSA:135] [KO:K04266]
            PDE [HSA:5153 5138 5139 5140 5141 5142 5143 5144 8654] [KO:K13755 K18283 K19021 K13296 K13293 K13762]
  PATHWAY   hsa04020(135+5153)  Calcium signaling pathway
            hsa04024(134+135+5139+5140+5141+5142+5143+5144)  cAMP signaling pathway
            hsa04080(134+135)  Neuroactive ligand-receptor interaction
            hsa04270(135)  Vascular smooth muscle contraction
METABOLISM  Enzyme: CYP1A2 [HSA:1544]; CYP3A4 [HSA:1576], CYP2E1 [HSA:1571]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AX Other dermatologicals
                 D11AX26 Caffeine
                  D07603  Caffeine citrate (USP) &lt;US&gt;
             N NERVOUS SYSTEM
              N06 PSYCHOANALEPTICS
               N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
                N06BC Xanthine derivatives
                 N06BC01 Caffeine
                  D07603  Caffeine citrate (USP) &lt;US&gt;
            Classification of Japanese OTC drugs [BR:br08313]
             Agents for nervous and sensory systems
              05 Alertness drug
               D07603  Caffeine citrate (USP)
            Risk category of Japanese OTC drugs [BR:br08312]
             Third-class OTC drugs
              Inorganic and organic chemicals
               Anhydrous caffeine
                D07603  Caffeine citrate (USP)
            Drug groups [BR:br08330]
             Respiratory system agent
              DG01616  Xanthine derivative
               DG01612  Xanthine-type central nervous system stimulant
                DG00974  Caffeine
                 D07603  Caffeine citrate
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00974  Caffeine
                D07603  Caffeine citrate
              DG02855  CYP2E1 substrate
               DG00974  Caffeine
                D07603  Caffeine citrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00974  Caffeine
                 D07603  Caffeine citrate
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Adenosine
                ADORA1
                 D07603  Caffeine citrate (USP) &lt;US&gt;
                ADORA2A
                 D07603  Caffeine citrate (USP) &lt;US&gt;
             Enzymes
              Hydrolases (EC3)
               Phosphodiesterases
                PDE
                 D07603  Caffeine citrate (USP) &lt;US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D07603
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D07603
            Drug groups [BR:br08330]
             Respiratory system agent
              DG01616  Xanthine derivative
               DG01612  Xanthine-type central nervous system stimulant
                DG00974  Caffeine
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00974  Caffeine
              DG02855  CYP2E1 substrate
               DG00974  Caffeine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00974  Caffeine
DBLINKS     CAS: 69-22-7
            PubChem: 51091913
            LigandBox: D07603
            NIKKAJI: J535.358K
ATOM        27
            1   C8y C    16.7313   -7.4914
            2   C8y C    16.7313   -8.9615
            3   C8y C    17.9214   -6.7913
            4   N4y N    15.4712   -7.0713
            5   N4y N    17.9214   -9.5915
            6   N5x N    15.4712   -9.3815
            7   N4y N    19.1815   -7.5614
            8   O5x O    17.9214   -5.4612
            9   C8x C    14.6311   -8.2614
            10  C1a C    14.9811   -5.7412
            11  C8y C    19.1815   -8.8915
            12  C1a C    17.9214  -11.0617
            13  C1a C    20.3716   -6.8613
            14  O5x O    20.4416   -9.5915
            15  C1d C    27.5800   -7.6300
            16  C1b C    26.3900   -8.3300
            17  C1b C    28.7700   -8.3300
            18  C6a C    28.2800   -6.4400
            19  O1a O    26.8800   -6.4400
            20  C6a C    25.2000   -7.7000
            21  C6a C    28.7700   -9.7300
            22  O6a O    27.5800   -5.2500
            23  O6a O    29.6800   -6.4400
            24  O6a O    23.9400   -8.4000
            25  O6a O    25.2000   -6.3000
            26  O6a O    30.0300  -10.4300
            27  O6a O    27.5800  -10.4300
BOND        27
            1     1   2 2
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     3   8 2
            8     4   9 1
            9     4  10 1
            10    5  11 1
            11    5  12 1
            12    7  13 1
            13   11  14 2
            14    6   9 2
            15    7  11 1
            16   15  16 1
            17   15  17 1
            18   15  18 1
            19   15  19 1
            20   16  20 1
            21   17  21 1
            22   18  22 1
            23   18  23 2
            24   20  24 1
            25   20  25 2
            26   21  26 1
            27   21  27 2
///
